Antisense Oligonucleotides Market Intelligence

Are you looking for answers on Antisense Oligonucleotides category?

Are you looking for answers on Antisense Oligonucleotides category?

  • What are the key trends in Antisense Oligonucleotides category?
  • Am I paying the right price?
  • Am I working with the right supplier?
  • What are the major challenges and risks in Antisense Oligonucleotides industry?
  • How is Antisense Oligonucleotides industry performing?

Over 50,000+ users trust Beroe

Report Coverage

  • Market Overview
  • Industry Trends
  • Supplier Landscape

Table of contents

  1. Executive Summary
  1. Antisense Oligonucleotides Market Overview
  1. Antisense Oligonucleotides Industry Trends
  1. Antisense Oligonucleotides Supplier Landscape

Want a more detailed personalised report?

Global Outlook on Antisense Oligonucleotides 

The Global Oligonucleotides market is expected to grow at a CAGR of ~10-11 percent during 2016-2021 which is driven by factors such as increased use in clinical and diagnostic applications , increasing R&D funding by pharma and biotech companies and growing grants from governments

North America holds the largest market size of oligonucleotides manufacturing market owing to established supply base, infrastructure and regional demand . Asia Pac is expected to grow at highest CAGR owing to increase in research on genomics and proteomics and increase in R&D funding.The Global Oligonucleotides market is expected to grow at a CAGR of ~10-11% during 2016-2021 which is driven by factors such as increased use in clinical and diagnostic applications , increasing R&D funding by pharma and biotech companies & growing grants from governments.

  • The Oligo manufacturing market is a very niche with very few players capable of producing commercial scale.
  • Being a technology driven industry, with reputation and experience standing tall for CMO selection, Specialist players (Niche players) are trying to increase the service capabilities by collaborating with Pharma to invest in new technologies.

Industry Trends

Increasing R&D

Changing regulations and pharma increasing focus on developing oligonucleotides in various neurological disorders increased the market for Antisense oligonucleotides. E.g.: Ionis Pharmaceutical is developing either alone or in collaborations with a strategic partner and has 25 percent of the total drugs in pipeline globally.

Regulatory Environment

The two largest regulatory bodies in the world, FDA and EU MHRA approved to use Oligonucleotides as drug. Of all the ASO molecules evaluated as of 2017 the regulatory authorities assessed that six has clear clinical benefits in rigorously controlled trials. E.g.: Kynamro, Eteplirsen, Defitelio, Spinraza, Vitravene, Macugen.

Technology advancements

New start-up companies with new technologies and rich patent portfolios are aiming to advance entirely new classes of oligo therapeutics. E.g.: Seattle based HaloBio developed multivalent RNA molecules (MV-RNA) for gene targeting. MV-RNA utilizes the same RISC pathway as siRNA, but expands gene targeting, eliminates, sense-strand off-target effects, and introduces the first “junction containing” structures to RNAi.

Supplier Landscape

North America holds the largest market size of oligonucleotides manufacturing market owing to established supply base, infrastructure and regional demand . Asia Pac is expected to grow at highest CAGR owing to increase in research on genomics and proteomics and increase in R&D funding. The ASO manufacturing market is highly competitive with the presence of several large players (e.g.: Nitto, Syngene) and emerging players (Manufacturing niche product segments).

 

Complimentary 12-month access to Beroe LiVE

Any more questions?

Get in touch with us quickly and easily.